Title: A Phase 2 Study of Ixazomib and Rituximab in Bruton Tyrosine Kinase Inhibitor Resistant Mantle Cell Lymphoma
Principal Investigator: Hun Ju Lee, MD, Assistant Professor of Medicine, Department of Lymphoma & Myeloma, the University of Texas MD Anderson Cancer Center, Houston, Texas
Description: Researchers are seeking to determine how well the combination of ixazomib and rituximab work for the treatment of relapsed/refractory mantle cell lymphoma in patients whose disease did not respond to Bruton tyrosine kinase (BTK) inhibitor treatment. The primary objective of this phase 2 trial is to evaluate the complete remission rate in patients with BTK inhibitor-refractory mantle cell lymphoma with ixazomib and rituximab after 16 weeks of therapy. Secondary outcomes include overall response rate, progression-free survival, overall survival, and incidence of toxicities. Eligible patients must have a histologically confirmed diagnosis of mantle cell lymphoma and lymph node or mass 2 cm or greater or bone marrow only disease as per morphology or flow cytometry. For a complete list of eligibility criteria please refer to the reference.
This study is sponsored by the University of Texas MD Anderson Cancer Center
Clinicaltrials.gov. Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma. NCT04047797. Accessed April 23, 2021.